Regeneron Pharmaceuticals Receives “Hold” Rating from TheStreet (REGN)
Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “hold” rating restated by stock analysts at TheStreet in a report issued on Monday, Analyst Ratings.Net reports.
The analysts wrote, “Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a hold with a ratings score of C+. The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company’s earnings per share.”
In other Regeneron Pharmaceuticals news, SVP Peter Powchik unloaded 20,668 shares of the stock on the open market in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $274.77, for a total value of $5,678,946.36. Following the completion of the sale, the senior vice president now directly owns 25,447 shares of the company’s stock, valued at approximately $6,992,072. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 2.08% on Monday, hitting $268.68. The stock had a trading volume of 942,786 shares. Regeneron Pharmaceuticals has a one year low of $154.16 and a one year high of $319.83. The stock has a 50-day moving average of $277.9 and a 200-day moving average of $274.7. The company has a market cap of $26.391 billion and a P/E ratio of 39.06.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings data on Tuesday, November 5th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $1.48. The company had revenue of $597.00 million for the quarter, compared to the consensus estimate of $501.93 million. During the same quarter in the previous year, the company posted $1.89 earnings per share. The company’s revenue for the quarter was up 39.6% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $3.83 EPS for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Barclays reiterated an “overweight” rating on shares of Regeneron Pharmaceuticals in a research note to investors on Friday. They now have a $340.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $323.00 to $344.00 in a research note to investors on Friday, December 20th. They now have an “outperform” rating on the stock. Finally, analysts at Piper Jaffray initiated coverage on shares of Regeneron Pharmaceuticals in a research note to investors on Wednesday, November 27th. They set an “overweight” rating and a $376.00 price target on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Buy” and an average price target of $299.74.
Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.